Premium
Tolerance and effectiveness of nivolumab after pediatric T‐cell replete, haploidentical, bone marrow transplantation: A case report
Author(s) -
Shad Aziza T.,
Huo Jeffrey S.,
Darcy Courtney,
AbuGhosh Amal,
Esposito Giuseppe,
Holuba MaryJo,
Robey Nancy,
Cooke Kenneth R.,
Symons Heather J.,
Chen Allen R.,
Llosa Nicolas J.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26257
Subject(s) - medicine , nivolumab , bone marrow transplantation , bone marrow transplant , transplantation , bone marrow , oncology , immunology , immunotherapy , immune system
To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22‐year‐old female with multiple‐relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post‐haplo) HSCT. Anti‐PD‐1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft‐versus‐host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.